Oncology Central

Phase III CELESTIAL trial of cabozantinib demonstrates significant overall survival benefit in HCC patients

The Phase III CELESTIAL trial by Ipsen (London, UK), investigating the use of cabozantinib as a liver cancer therapy, has been halted due to “compelling evidence of efficacy”, after the drug met its primary endpoint of overall survival (OS).

The data was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (18th-20th January, CA, USA). Ewan McDowall, General Manager of Ipsen UK & Ireland, explained the significance of the results: “These data will form the basis of our licence submission, bringing us one step closer to making this positive new treatment available to patients in the UK & Ireland.”

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.